热门资讯> 正文

Adagio Therapeutics GAAP EPS—1.81美元

2024-03-28 19:23

Adagio Therapeutics press release (NASDAQ:IVVD): FY GAAP EPS of -$1.81.
Cash and cash equivalents were $200.6 million as of December 31, 2023.
Based on current operating plans and excluding anticipated cash collections from PEMGARDA sales, Invivyd expects its existing total cash and cash equivalents will enable the company to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2024.

More on Adagio Therapeutics

Morgan Stanley ups Invivyd to overweight, cites FDA EUA decision
Invivyd stock soars on FDA EUA for COVID-19 prophylaxis drug
Seeking Alpha’s Quant Rating on Adagio Therapeutics
Historical earnings data for Adagio Therapeutics
Financial information for Adagio Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。